Learn about available clinical trials
A Phase 3 clinical trial evaluating the ExPEC9V vaccine for the prevention of invasive E. coli infections in adults aged 60 and older, assessing efficacy, safety, and immunogenicity.
A clinical trial evaluating a new treatment for complicated urinary tract infections and the use of probiotics to reduce recurrences in women, assessing efficacy and safety.
A Phase 3 clinical trial evaluating TAR-200 in combination with cetrelimab versus standard chemoradiotherapy in patients with muscle-invasive bladder cancer, with the aim of preserving the bladder and improving tumor control.
A phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of niraparib in combination with abiraterone acetate and prednisone (AA-P) and androgen deprivation therapy (ADT), versus abiraterone + prednisone + ADT in patients with metastatic castration-sensitive prostate cancer (mCSPC) with alterations in DNA repair genes (DNA repair defects or DRDs).
Phase 2b study evaluating the efficacy and safety of TAR-200 (with or without cetrelimab) in patients with high-risk, non-muscle invasive bladder cancer who have not responded to BCG treatment and who are unable or unwilling to undergo radical cystectomy (complete removal of the bladder).
Phase III clinical trial evaluating the efficacy and safety of ONCOFID-P-B administered by intravesical instillation in patients with bladder carcinoma in situ who do not respond to BCG. The study seeks to offer a conservative alternative to radical cystectomy in patients with limited therapeutic options, analyzing the complete response rate and long-term safety profile.